JP2012508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508215A5
JP2012508215A5 JP2011535129A JP2011535129A JP2012508215A5 JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5 JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5
Authority
JP
Japan
Prior art keywords
salt
salt according
optionally
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011535129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064889 external-priority patent/WO2010055027A2/en
Publication of JP2012508215A publication Critical patent/JP2012508215A/ja
Publication of JP2012508215A5 publication Critical patent/JP2012508215A5/ja
Withdrawn legal-status Critical Current

Links

JP2011535129A 2008-11-11 2009-11-10 有機化合物 Withdrawn JP2012508215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168862.4 2008-11-11
EP08168862 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089480A Division JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Publications (2)

Publication Number Publication Date
JP2012508215A JP2012508215A (ja) 2012-04-05
JP2012508215A5 true JP2012508215A5 (cg-RX-API-DMAC7.html) 2012-12-20

Family

ID=42062355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011535129A Withdrawn JP2012508215A (ja) 2008-11-11 2009-11-10 有機化合物
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Country Status (20)

Country Link
US (2) US8680146B2 (cg-RX-API-DMAC7.html)
EP (1) EP2358660A2 (cg-RX-API-DMAC7.html)
JP (2) JP2012508215A (cg-RX-API-DMAC7.html)
KR (1) KR20110086142A (cg-RX-API-DMAC7.html)
CN (2) CN102256933A (cg-RX-API-DMAC7.html)
AU (1) AU2009315735B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921533A2 (cg-RX-API-DMAC7.html)
CA (1) CA2741974A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001041A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382154A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011121A (cg-RX-API-DMAC7.html)
IL (1) IL212073A0 (cg-RX-API-DMAC7.html)
MA (1) MA32877B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011004924A (cg-RX-API-DMAC7.html)
NZ (1) NZ591999A (cg-RX-API-DMAC7.html)
PE (1) PE20120012A1 (cg-RX-API-DMAC7.html)
RU (1) RU2543621C2 (cg-RX-API-DMAC7.html)
TN (1) TN2011000187A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010055027A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102272B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609659C (en) 2005-05-26 2014-01-28 Neuron Systems, Inc. Azanaphthalenes, compositions and methods for treating retinal disease
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
EP2896609B1 (en) 2009-07-24 2018-06-27 ratiopharm GmbH Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CA2815634A1 (en) 2010-10-28 2012-05-03 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP2964210B1 (en) 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3025887C (en) 2016-05-31 2022-06-28 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
CA3103153A1 (en) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
US20240262783A1 (en) * 2021-05-31 2024-08-08 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
JP4503184B2 (ja) * 1998-11-11 2010-07-14 ノヴァルティス アーゲー 2−アミノ−2−[2−(4−c2−20−アルキル−フェニル)エチル]プロパン−1,3−ジオール類の製造
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
AU2006297130B2 (en) * 2005-09-30 2009-12-24 Novartis Ag DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection
EP2046315B1 (en) * 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
US7985586B2 (en) * 2008-02-04 2011-07-26 Georgia Health Sciences University Oligodendrocyte precursor cell composition and methods of use
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物

Similar Documents

Publication Publication Date Title
JP2012508215A5 (cg-RX-API-DMAC7.html)
RU2011123365A (ru) Соли финголимода
RU2011123371A (ru) Кристаллические формы гидрохлорида финголимода
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
JP2018035160A5 (cg-RX-API-DMAC7.html)
JP2011527333A5 (cg-RX-API-DMAC7.html)
JP2010514829A5 (cg-RX-API-DMAC7.html)
ME02275B (me) Polimorfni oblik rotigotina
JP2010518061A5 (cg-RX-API-DMAC7.html)
JP2012523395A5 (cg-RX-API-DMAC7.html)
JP2009084270A5 (cg-RX-API-DMAC7.html)
JP2017527578A5 (cg-RX-API-DMAC7.html)
JP2011510014A5 (cg-RX-API-DMAC7.html)
JP2010514831A5 (cg-RX-API-DMAC7.html)
RU2011145054A (ru) Кристаллические формы саксаглиптина
JP2015145426A5 (cg-RX-API-DMAC7.html)
JP2010514832A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2014524442A5 (cg-RX-API-DMAC7.html)
JP2011516477A5 (cg-RX-API-DMAC7.html)
JP2010529203A5 (cg-RX-API-DMAC7.html)
JP2020510661A5 (cg-RX-API-DMAC7.html)
JP2016503010A5 (cg-RX-API-DMAC7.html)
JP2010522710A5 (cg-RX-API-DMAC7.html)
JP2020534270A5 (cg-RX-API-DMAC7.html)